NCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
Emory University
Memorial Sloan Kettering Cancer Center
Maria Sklodowska-Curie National Research Institute of Oncology